Krishna Institute of Medical Sciences Ltd Stock Price Today (NSE: KIMS)
Fundamental Score
Krishna Institute of Medical Sciences Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Krishna Institute of Medical Sciences Ltd share price today is ₹692.50, up +0.00% on NSE/BSE as of 20 February 2026. Krishna Institute of Medical Sciences Ltd (KIMS) is a Large-cap company in the Hospital sector with a market capitalisation of ₹27.61K (Cr). The 52-week high for KIMS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 83.99x, KIMS is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 18.48% and a debt-to-equity ratio of 1.40.
Krishna Institute of Medical Sciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Krishna Institute of Medical Sciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Krishna Institute of Medical Sciences Share Price Analysis: A Conservative View
Healthcare, particularly specialized hospital chains, faces a unique challenge: balancing patient care with profitability. The pricing power hospitals possess, while seemingly robust, is increasingly scrutinized by regulators and insurance providers. This analysis examines the current valuation of Krishna Institute of Medical Sciences share price from a conservative value investing perspective, focusing on capital preservation. As of the latest data, the share price stands at ₹595.150024.
A key metric demanding attention is Krishna Institute of Medical Sciences Ltd's Price-to-Earnings (PE) ratio of 83.99. This valuation appears significantly elevated compared to broader market averages and suggests the market has priced in substantial future growth. When assessing peers, such as
Nephro Care India Limited, qualitative factors like management quality become paramount. A deeper dive into the leadership track record and capital allocation decisions of both companies is essential to justify the premium ascribed to Krishna Institute of Medical Sciences Ltd's valuation. Scrutinizing their ability to navigate regulatory hurdles and adapt to evolving healthcare landscapes is crucial.Krishna Institute of Medical Sciences Ltd boasts a Return on Capital Employed (ROCE) of 15.0%. This indicates the company's efficiency in generating profits from its capital investments. From a moat perspective, consistent ROCE above the cost of capital suggests a degree of competitive advantage. However, in the hospital sector, such performance must be examined closely. Is it derived from specialized services, geographic dominance, or superior cost management? Sustaining this ROCE is vital for long-term value creation.
In conclusion, the high PE ratio warrants caution. While the 15.0% ROCE is encouraging, further investigation into its sustainability and sources is crucial. This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, designed to provide a rigorous assessment of the company's financial health and investment potential. Investors should conduct thorough due diligence and consider their individual risk tolerance before making any investment decisions. This analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Krishna Institute of Medical Sciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KIMS across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.48%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.00%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.57%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (23.59%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (22.01% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.23% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.01% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Institutional Confidence (FII+DII: 47.15%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 83.99x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-37.45%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 1.40)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Negative Free Cash Flow (₹-228.14 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Krishna Institute of Medical Sciences Ltd Financial Statements
Comprehensive financial data for Krishna Institute of Medical Sciences Ltd including income statement, balance sheet and cash flow
About KIMS (Krishna Institute of Medical Sciences Ltd)
Krishna Institute of Medical Sciences Ltd (KIMS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Hospital sector with a current market capitalisation of ₹27.61K (Cr). Krishna Institute of Medical Sciences Ltd has delivered a Return on Equity (ROE) of 18.48% and a ROCE of 15.00%. The debt-to-equity ratio stands at 1.40, reflecting the company's capital structure. Investors tracking KIMS share price can monitor key metrics including P/E ratio, promoter holding of 34.11%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
KIMS Share Price: Frequently Asked Questions
What is the current share price of Krishna Institute of Medical Sciences Ltd (KIMS)?
As of 20 Feb 2026, 02:51 pm IST, Krishna Institute of Medical Sciences Ltd share price is ₹692.50. The KIMS stock has a market capitalisation of ₹27.61K (Cr) on NSE/BSE.
Is KIMS share price Overvalued or Undervalued?
KIMS share price is currently trading at a P/E ratio of 83.99x, compared to the industry average of 52.84x. Based on this relative valuation, the Krishna Institute of Medical Sciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of KIMS share price?
The 52-week high of KIMS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Krishna Institute of Medical Sciences Ltd share price?
Key factors influencing KIMS share price include quarterly earnings growth (Sales Growth: 23.59%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Krishna Institute of Medical Sciences Ltd a good stock for long-term investment?
Krishna Institute of Medical Sciences Ltd shows a 5-year Profit Growth of 25.01% and an ROE of 18.48%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.40 before investing in KIMS shares.
How does Krishna Institute of Medical Sciences Ltd compare with its industry peers?
Krishna Institute of Medical Sciences Ltd competes with major peers in the Hospital. Investors should compare KIMS share price P/E of 83.99x and ROE of 18.48% against the industry averages to determine competitive standing.
What is the P/E ratio of KIMS and what does it mean?
KIMS share price has a P/E ratio of 83.99x compared to the industry average of 52.84x. Investors pay ₹84 for every ₹1 of annual earnings.
How is KIMS performing according to Bull Run's analysis?
KIMS has a Bull Run fundamental score of 45.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does KIMS belong to?
KIMS operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Krishna Institute of Medical Sciences Ltd share price.
What is Return on Equity (ROE) and why is it important for KIMS?
KIMS has an ROE of 18.48%, which indicates excellent management efficiency. ROE measures how efficiently Krishna Institute of Medical Sciences Ltd generates profits from shareholders capital.
How is KIMS debt-to-equity ratio and what does it indicate?
KIMS has a debt-to-equity ratio of 1.40, which indicates high leverage that increases financial risk.
What is KIMS dividend yield and is it a good dividend stock?
KIMS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Krishna Institute of Medical Sciences Ltd shares.
How has KIMS share price grown over the past 5 years?
KIMS has achieved 5-year growth rates of: Sales Growth 22.01%, Profit Growth 25.01%, and EPS Growth 23.23%.
What is the promoter holding in KIMS and why does it matter?
Promoters hold 34.11% of KIMS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Krishna Institute of Medical Sciences Ltd.
What is KIMS market capitalisation category?
KIMS has a market capitalisation of ₹27606 crores, placing it in the Large-cap category.
How volatile is KIMS stock?
KIMS has a beta of N/A. A beta > 1 suggests the Krishna Institute of Medical Sciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is KIMS operating profit margin trend?
KIMS has a 5-year average Operating Profit Margin (OPM) of 27.57%, indicating the company's operational efficiency.
How is KIMS quarterly performance?
Recent quarterly performance shows Krishna Institute of Medical Sciences Ltd YoY Sales Growth of 23.59% and YoY Profit Growth of -37.45%.
What is the institutional holding pattern in KIMS?
KIMS has FII holding of 15.03% and DII holding of 32.12%. Significant institutional holding often suggests professional confidence in the Krishna Institute of Medical Sciences Ltd stock.